Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLCN2 | P51788 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25950470 | 0.90 | CLCN2 (0.31) | CLCN2PDCD1CD274 | |
| SCHEMBL25950435 | 0.85 | THRB (0.43) | CLCN2TSHRTDP1PDCD1CD274 | |
| SCHEMBL24132911 | 0.84 | THRA (0.36) | THRATHRB | |
| SCHEMBL25950449 | 0.84 | CLCN2 (0.31) | CLCN2 | |
| SCHEMBL25950447 | 0.80 | CLCN2 (0.30) | CLCN2 | |
| SCHEMBL25950450 | 0.76 | — | — | |
| SCHEMBL25950439 | 0.75 | THRB (0.37) | THRATHRB | |
| SCHEMBL25950349 | 0.75 | CLCN2 (0.32) | CLCN2THRATHRB | |
| SCHEMBL24132839 | 0.74 | THRA (0.41) | THRATHRB | |
| SCHEMBL25950102 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242471-A1 | THYROMIMETICS | TPO, THOP1, THRB | CLCN2 3860/4885TSHR 4/4885TDP1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.